Curis Reports Dosing of First Patient in Phase 1 Trial of CUDC-907 in Patients with Advanced/Relapsed Solid Tumors

By: via Benzinga
Curis, Inc. (Nasdaq: CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.